cas 1158233-60-3|| where to buy Methyl2-(1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl)acetate

Nom du produit:Methyl2-(1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl)acetate

IUPAC Name:methyl 2-[1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate

: CAS：1158233-60-3; Formule moléculaire：C12H11ClN2O3; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM643356-5g	in stock	Ǌțũ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1158233-60-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1158233-60-3; Formule moléculaire:C12H11ClN2O3; Point de fusion:-; Code SMILES:COC(=O)CC1=NN(C(O)=C1)C1=C(Cl)C=CC=C1; Densité:

: Numéro de catalogue:CM643356; Poids moléculaire:266.68; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Setanaxib; Genkyotex SA’s Setanaxib (GKT 831) is a small molecule NOX inhibitor currently in Phase III clinical trials and a potential treatment solution for Primary Biliary Cholangitis (PBC). PBC is a chronic and progressive condition characterized by the inflammation and subsequent destruction of the small bile ducts within the liver. Setanaxib is a novel selective inhibitor of NADPH oxidase (NOX) 1 and 4 isoforms, enabling the downregulation of multiple fibrogenic and inflammatory pathways to prevent progression of liver fibrosis. The mechanism of action of setanaxib involves both anti-fibrotic and anti-inflammatory effects.